Le Lézard
Classified in: Health, Science and technology
Subjects: TRI, PLW

Cantargia Obtains Patent Approval in USA for the Antibody CAN04 in Development for Treatment of Cancer

STOCKHOLM, Oct. 06, 2017 /PRNewswire/ --

Cantargia AB ("Cantargia") today announces that the United States Patent and Trademark Office ("USPTO") has granted the company's patent application directed to the product candidate CAN04. The antibody CAN04 is targeted against the molecule IL1RAP expressed in a large number of cancer diseases. The formal approval follows the intention to grant that USPTO issued in June 2017.

The granted patent no. US 9,796,783 concerns the composition of the product candidate CAN04. The patent gives protection in USA until 2035. In addition to the patent granted in USA, Cantargia obtained approval in Europe in August 2017. The application has also been submitted in a large number of additional territories such as Japan and China. In these territories, examination is ongoing.

"Thanks to the approvals in both Europe and the US, we have a very strong patent position in the most important territories," says Göran Forsberg, CEO of Cantargia. "We now have approvals regarding the treatment of various cancers with antibodies against IL1RAP in general as well as for the CAN04 antibody"

For further information, please contact

Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

This constitutes information that Cantargia is required to publish under the EU's Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication through the above contact person at 11.00 CET on 6 October 2017. 

About us

Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing antibody-based treatments for life threatening diseases. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein "IL1RAP", in leukemia stem cells, later research has also identified IL1RAP in a large number of other forms of cancer. The lead compound, CAN04 directed against IL1RAP, will be investigated in the CANFOUR phase I/IIa clinical trial in with primary focus on non-small lung cancer and pancreatic cancer. CAN04 has a dual mechanism of action, it blocks IL1RAP function and stimulates the immune system to eradicate tumor cells. Cantargia's second project is in discovery phase with the goal to develop an IL1RAP binding antibody optimized for therapy of autoimmunity and inflammatory diseases.

Cantargia is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company's Certified Adviser. More information about Cantargia is available at http://www.cantargia.com.

This information was brought to you by Cision http://news.cision.com

The following files are available for download:




These press releases may also interest you

at 18:15
At a November meeting of business leaders in Wisconsin, Mike Clumpner, Chairman of privately held Nova Molecular Technologies discussed how Nova has quickly achieved a sustainable and advantaged position as one of the world's largest manufacturers of...

at 18:11
The Alliance to Fight the 40 | Don't Tax My Health Care today applauded Congressional leaders for including a two-year delay of the 40% "Cadillac Tax" in their bill to end the government shutdown and provide funding through February 8th. This...

at 17:21
Frost & Sullivan's latest analysis of the European prenatal genetic testing market point to advancements in technologies, such as next-generation sequencing techniques (NGS) and use of non-invasive prenatal testing (NIPT), as the key factors...

at 17:17
Stanton Optical, known for delivering the highest quality products and services for customers in eyewear, sunglasses, and contact lenses at affordable prices, is opening a new optical store in Boynton Beach, Florida in early February. This will bring...

at 17:04
Arena Pharmaceuticals, Inc. , today announced that it will host a key opinion leader (KOL) event for investors focused on sphingosine-1-phosphate (S1P) receptor modulation in the treatment of autoimmune diseases in New York City on Monday, January...

at 17:00
Community Healthcare Trust Incorporated today announced that on Thursday evening, February 22, 2018, after the market closes, it will report results for the fourth quarter of 2017.  On February 23, 2018, at 9:00 a.m. Central Time, Community...

News published on 6 october 2017 at 05:16 and distributed by: